153 related articles for article (PubMed ID: 27141369)
1. Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer.
Park JH; McMillan DC; Edwards J; Horgan PG; Roxburgh CS
Oncoimmunology; 2016 Mar; 5(3):e1098801. PubMed ID: 27141369
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer.
Park JH; McMillan DC; Powell AG; Richards CH; Horgan PG; Edwards J; Roxburgh CS
Clin Cancer Res; 2015 Feb; 21(4):882-8. PubMed ID: 25473000
[TBL] [Abstract][Full Text] [Related]
3. Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer.
Park JH; van Wyk H; Roxburgh CSD; Horgan PG; Edwards J; McMillan DC
Br J Cancer; 2017 May; 116(11):1444-1450. PubMed ID: 28427085
[TBL] [Abstract][Full Text] [Related]
4. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
Park JH; Richards CH; McMillan DC; Horgan PG; Roxburgh CSD
Ann Oncol; 2014 Mar; 25(3):644-651. PubMed ID: 24458470
[TBL] [Abstract][Full Text] [Related]
5. The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer.
Gujam FJ; Edwards J; Mohammed ZM; Going JJ; McMillan DC
Br J Cancer; 2014 Jul; 111(1):157-65. PubMed ID: 24874480
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer.
Jakubowska K; Kisielewski W; Kańczuga-Koda L; Koda M; Famulski W
Oncol Lett; 2017 Sep; 14(3):3869-3877. PubMed ID: 28927159
[TBL] [Abstract][Full Text] [Related]
7. The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
van Wyk HC; Park JH; Edwards J; Horgan PG; McMillan DC; Going JJ
Br J Cancer; 2016 Jul; 115(2):156-63. PubMed ID: 27299960
[TBL] [Abstract][Full Text] [Related]
8. Preoperative, biopsy-based assessment of the tumour microenvironment in patients with primary operable colorectal cancer.
Park JH; van Wyk H; McMillan DC; Edwards J; Orange C; Horgan PG; Roxburgh CS
J Pathol Clin Res; 2020 Jan; 6(1):30-39. PubMed ID: 31486287
[TBL] [Abstract][Full Text] [Related]
9. The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer.
van Wyk HC; Roseweir A; Alexander P; Park JH; Horgan PG; McMillan DC; Edwards J
Ann Surg Oncol; 2019 Dec; 26(13):4397-4404. PubMed ID: 31605345
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma.
Zhang XM; Song LJ; Shen J; Yue H; Han YQ; Yang CL; Liu SY; Deng JW; Jiang Y; Fu GH; Shen WW
Hum Pathol; 2018 Dec; 82():104-112. PubMed ID: 30036594
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer.
Roxburgh CS; Salmond JM; Horgan PG; Oien KA; McMillan DC
Ann Surg; 2009 May; 249(5):788-93. PubMed ID: 19387324
[TBL] [Abstract][Full Text] [Related]
12. The Glasgow Microenvironment Score: an exemplar of contemporary biomarker evolution in colorectal cancer.
Knight K; Bigley C; Pennel K; Hay J; Maka N; McMillan D; Park J; Roxburgh C; Edwards J
J Pathol Clin Res; 2024 Jul; 10(4):e12385. PubMed ID: 38853386
[TBL] [Abstract][Full Text] [Related]
13. Histopathological tumour microenvironment score independently predicts outcome in primary operable colorectal cancer.
Hatthakarnkul P; Pennel K; Alexander P; van Wyk H; Roseweir A; Inthagard J; Hay J; Andersen D; Maka N; Park J; Roxburgh C; Thuwajit C; McMillan D; Edwards J
J Pathol Clin Res; 2024 May; 10(3):e12374. PubMed ID: 38650367
[TBL] [Abstract][Full Text] [Related]
14. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment.
Park JH; Powell AG; Roxburgh CS; Horgan PG; McMillan DC; Edwards J
Br J Cancer; 2016 Mar; 114(5):562-70. PubMed ID: 26859693
[TBL] [Abstract][Full Text] [Related]
15. Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host.
Park JH; van Wyk H; McMillan DC; Quinn J; Clark J; Roxburgh CS; Horgan PG; Edwards J
Clin Cancer Res; 2017 Apr; 23(7):1698-1709. PubMed ID: 27678454
[No Abstract] [Full Text] [Related]
16. The clinical utility of the local inflammatory response in colorectal cancer.
Richards CH; Roxburgh CS; Powell AG; Foulis AK; Horgan PG; McMillan DC
Eur J Cancer; 2014 Jan; 50(2):309-19. PubMed ID: 24103145
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
Watson MM; Lea D; Gudlaugsson E; Skaland I; Hagland HR; Søreide K
Cancer Immunol Immunother; 2020 Aug; 69(8):1627-1637. PubMed ID: 32314040
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.
Zou MX; Lv GH; Wang XB; Huang W; Li J; Jiang Y; She XL
Neurosurgery; 2019 Jun; 84(6):E318-E333. PubMed ID: 30032257
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive values of the immunoscore in patients with rectal cancer.
Anitei MG; Zeitoun G; Mlecnik B; Marliot F; Haicheur N; Todosi AM; Kirilovsky A; Lagorce C; Bindea G; Ferariu D; Danciu M; Bruneval P; Scripcariu V; Chevallier JM; Zinzindohoué F; Berger A; Galon J; Pagès F
Clin Cancer Res; 2014 Apr; 20(7):1891-9. PubMed ID: 24691640
[TBL] [Abstract][Full Text] [Related]
20. The local inflammatory response in colorectal cancer - Type, location or density? A systematic review and meta-analysis.
Alexander PG; McMillan DC; Park JH
Cancer Treat Rev; 2020 Feb; 83():101949. PubMed ID: 31869737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
